Overcoming Disparities in Using SGLT2 Inhibitors for Cardiorenal Protection in Persons With and Without Type 2 Diabetes
{{output}}
Despite mounting evidence supporting the cardio-kidney benefits of sodium/glucose cotransporter 2 (SGLT2) inhibitors, significant disparities in their use exist among people with type 2 diabetes (T2D), cardiovascular or kidney disease that reveals a significan... ...
